Q1 Earnings Forecast for Acelyrin Issued By HC Wainwright

Acelyrin, Inc. (NASDAQ:SLRN) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Acelyrin in a research report issued on Tuesday, January 7th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.44) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $6.00 target price on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Acelyrin’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.15) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at ($1.04) EPS.

SLRN has been the subject of a number of other reports. Citigroup cut their price objective on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Tuesday. Wells Fargo & Company cut their target price on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $9.60.

Acelyrin Trading Down 2.7 %

Shares of SLRN opened at $2.14 on Thursday. The business’s 50 day moving average is $4.16 and its 200 day moving average is $4.84. Acelyrin has a 12-month low of $1.91 and a 12-month high of $8.89. The company has a market capitalization of $214.70 million, a PE ratio of -0.87 and a beta of 1.94.

Institutional Trading of Acelyrin

Several hedge funds have recently modified their holdings of SLRN. Bank of New York Mellon Corp raised its position in shares of Acelyrin by 22.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 223,395 shares of the company’s stock valued at $985,000 after buying an additional 41,058 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in Acelyrin during the second quarter valued at approximately $49,000. Rhumbline Advisers raised its position in Acelyrin by 25.3% during the second quarter. Rhumbline Advisers now owns 108,384 shares of the company’s stock valued at $478,000 after purchasing an additional 21,859 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Acelyrin in the 2nd quarter valued at approximately $693,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Acelyrin in the 2nd quarter worth approximately $590,000. 87.31% of the stock is owned by hedge funds and other institutional investors.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.